IDEAS home Printed from https://ideas.repec.org/p/chy/respap/81cherp.html
   My bibliography  Save this paper

Methods for the estimation of the NICE cost effectiveness threshold

Author

Listed:
  • Karl Claxton

    (Centre for Health Economics and Department of Economics and Related Studies, University of York, UK)

  • Steve Martin

    (Department of Economics and Related Studies, University of York, UK)

  • Marta Soares

    (Centre for Health Economics, University of York, UK)

  • Nigel Rice

    (Centre for Health Economics, University of York, UK)

  • Eldon Spackman

    (Centre for Health Economics, University of York, UK)

  • Sebastian Hinde

    (Centre for Health Economics, University of York, UK)

  • Nancy Devlin

    (Office of Health Economics, London, UK)

  • Peter C Smith

    (Imperial College, London, UK)

  • Mark Sculpher

    (Centre for Health Economics, University of York, UK)

Abstract

A study by health economists at the University of York has, for the first time, produced an estimate of the impact on other NHS patients of new and more costly drugs and other treatments. This research suggests a refinement of the way the National Institute for Health and Clinical Excellence (NICE) gauges the cost-effectiveness of new interventions. It also has implications for the prices that the NHS can afford to pay for new drugs when the value-based pricing scheme for all new drugs is introduced by the Government in 2014.

Suggested Citation

  • Karl Claxton & Steve Martin & Marta Soares & Nigel Rice & Eldon Spackman & Sebastian Hinde & Nancy Devlin & Peter C Smith & Mark Sculpher, 2013. "Methods for the estimation of the NICE cost effectiveness threshold," Working Papers 081cherp, Centre for Health Economics, University of York.
    • Handle: RePEc:chy:respap:81cherp
    as

    Download full text from publisher

    File URL: http://www.york.ac.uk/media/che/documents/papers/researchpapers/CHERP81_methods_estimation_NICE_costeffectiveness_threshold_(Nov2013).pdf
    File Function: First version, 2013
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. Paul Dolan & Claire Gudex & Paul Kind & Alan Williams, 1995. "A social tariff for EuroQol: results from a UK general population survey," Working Papers 138chedp, Centre for Health Economics, University of York.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Gisela Kobelt & J. Berg & P. Lindgren, 2006. "Costs and quality of life in multiple sclerosis in The Netherlands," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 7(02), pages 55-64, July.
    2. Emma McIntosh, 2006. "Using Discrete Choice Experiments within a Cost-Benefit Analysis Framework," PharmacoEconomics, Springer, vol. 24(9), pages 855-868, September.
    3. Lieven Annemans & Mélanie Brignone & Sylvain Druais & Ann Pauw & Aline Gauthier & Koen Demyttenaere, 2014. "Cost-Effectiveness Analysis of Pharmaceutical Treatment Options in the First-Line Management of Major Depressive Disorder in Belgium," PharmacoEconomics, Springer, vol. 32(5), pages 479-493, May.
    4. Gisela Kobelt & J. Berg & P. Lindgren & G. Izquierdo & O. Sánchez-Soliño & J. Pérez-Miranda & M. Casado, 2006. "Costs and quality of life of multiple sclerosis in Spain," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 7(2), pages 65-74, July.
    5. José Nunes, 1998. "Economic evaluation of rehabilitation: The quality of life approach using EuroQol," International Advances in Economic Research, Springer;International Atlantic Economic Society, vol. 4(2), pages 192-201, May.
    6. Brazier, John & Roberts, Jennifer & Deverill, Mark, 2002. "The estimation of a preference-based measure of health from the SF-36," Journal of Health Economics, Elsevier, vol. 21(2), pages 271-292, March.
    7. Lena Lundberg & Magnus Johannesson & Dag G.L. Isacson & Lars Borgquist, 1999. "The Relationship between Health-state Utilities and the SF-12 in a General Population," Medical Decision Making, , vol. 19(2), pages 128-140, April.
    8. Garry Barton & Tracey Sach & Michael Doherty & Anthony Avery & Claire Jenkinson & Kenneth Muir, 2008. "An assessment of the discriminative ability of the EQ-5D index , SF-6D, and EQ VAS, using sociodemographic factors and clinical conditions," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 9(3), pages 237-249, August.
    9. Dennis Petrie & Chris Doran & Anthony Shakeshaft & Rob Sanson-Fisher, 2007. "The relationship between alcohol consumption and self-reported health status using the EQ5D," Dundee Discussion Papers in Economics 204, Economic Studies, University of Dundee.
    10. Nick Bansback & Huiying Sun & Daphne P. Guh & Xin Li & Bohdan Nosyk & Susan Griffin & Paul G. Barnett & Aslam H. Anis, 2008. "Impact of the recall period on measuring health utilities for acute events," Health Economics, John Wiley & Sons, Ltd., vol. 17(12), pages 1413-1419, December.
    11. Gisela Kobelt & Jenny Berg & Peter Lindgren & M. Battaglia & C. Lucioni & A. Uccelli, 2006. "Costs and quality of life of multiple sclerosis in Italy," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 7(2), pages 45-54, July.
    12. Gisela Kobelt & Jenny Berg & P. Lindgren & J. Kerrigan & N. Russell & R. Nixon, 2006. "Costs and quality of life of multiple sclerosis in the United Kingdom," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 7(02), pages 96-104, July.
    13. N J Devlin & P Hansen & P Kind & A H Williams, 2000. "The health state preferences and logistical inconsistencies of New Zealanders: a tale of two tariffs," Working Papers 180chedp, Centre for Health Economics, University of York.
    14. Josue Mbonigaba, 2012. "The Cost-effectiveness of Intervening in Low and High HIV Prevalence Areas in South Africa," Working Papers 304, Economic Research Southern Africa.
    15. Susan Cleary & Gavin Mooney & Di McIntyre, 2010. "Equity and efficiency in HIV‐treatment in South Africa: the contribution of mathematical programming to priority setting," Health Economics, John Wiley & Sons, Ltd., vol. 19(10), pages 1166-1180, October.
    16. José Luis Pinto‐Prades & Neil McHugh & Cam Donaldson & Sarkis Manoukian, 2019. "Sequence effects in time trade‐off valuation of hypothetical health states," Health Economics, John Wiley & Sons, Ltd., vol. 28(11), pages 1308-1319, November.
    17. Kobelt, G., 2013. "Health Economics: An Introduction to Economic Evaluation," Monographs, Office of Health Economics, number 000004.
    18. Adam Oliver, 2013. "Testing Procedural Invariance In The Context Of Health," Health Economics, John Wiley & Sons, Ltd., vol. 22(3), pages 272-288, March.
    19. Garry R. Barton & Tracey H. Sach & Anthony J. Avery & Claire Jenkinson & Michael Doherty & David K. Whynes & Kenneth R. Muir, 2008. "A comparison of the performance of the EQ‐5D and SF‐6D for individuals aged ≥ 45 years," Health Economics, John Wiley & Sons, Ltd., vol. 17(7), pages 815-832, July.
    20. John Yfantopoulos & Athanasios Chantzaras, 2020. "Health-related quality of life and health utilities in insulin-treated type 2 diabetes: the impact of related comorbidities/complications," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(5), pages 729-743, July.

    More about this item

    Keywords

    cost-effectiveness;

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:chy:respap:81cherp. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Gill Forder (email available below). General contact details of provider: https://edirc.repec.org/data/chyoruk.html .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.